We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
7
1 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
2007
Enrolling By Invitation
1
14.3%
Recruiting
2
28.6%
Terminated
4
57.1%
No approval data available
- Ryvu Therapeutics SA has terminated its Phase 2 POTAMI-61 study of RVU120 in intermediate- or high-risk primary or secondary myelofibrosis. - The open-label trial tested oral RVU120 as monotherapy and combined with the JAK inhibitor ruxolitinib, with no placebo arm and non-random allocation. - The study record, first submitted 2024-04-29 and last updated 2026-09-15, is now listed as terminated before planned completion, pressuring the blood cancer pipeline.
